The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor

Cancer

Volumn 112, Issue 4, 2008, Pages 800-805

  Dash, Atreya ^a   Carver, Brett S ^a   Stasi, Jason ^a   Bajorin, Dean F ^a   Motzer, Robert J ^a   Bosl, George J ^a   Sheinfeld, Joel ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Chemotherapy; Germ cell tumor; Retroperitoneal lymph node dissection; Teratoma

Indexed keywords

CHORIONIC GONADOTROPIN BETA SUBUNIT; CISPLATIN; ETOPOSIDE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RELAPSE; CLINICAL ARTICLE; FOLLOW UP; HUMAN; LYMPH NODE DISSECTION; MALE; MULTIPLE CYCLE TREATMENT; NON SEMINOMATOUS GERMINOMA; PRIORITY JOURNAL; RETROPERITONEAL CANCER; TERATOMA; TREATMENT INDICATION; TREATMENT OUTCOME;

CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; HUMANS; LYMPH NODE EXCISION; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, GERM CELL AND EMBRYONAL; SURVIVAL RATE; TERATOMA; TESTICULAR NEOPLASMS; TREATMENT OUTCOME;

EID: 39049133078     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23233     Document Type: Article

References (19)

1. Davis BE, Herr HW, Fair WR, Bosl GJ. The management of patients with nonseminomatous germ cell tumors of the testis with serologic disease only after orchiectomy. J Urol. 1994;152:111-113.
2. Rabbani F, Farivar-Mohseni H, Leon A, Motzer RJ, Bosl GJ, Sheinfeld J. Clinical outcome after retroperitoneal lymphadenectomy of patients with pure testicular teratoma. Urology. 2003;62:1092-1096.
3. Saxman SB, Nichols CR, Foster RS, Messemer JE, Donohue JP, Einhorn LH. The management of patients with clinical stage I nonseminomatous testicular tumors and persistently elevated serologic markers. J Urol. 1996;155:587-589.
4. National Comprehensive Cancer Network. Testicular Cancer.National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, version 1, 2007. Available at URL: http://www.nccn.org/professionals/physician_gls/PDF/ testicular.pdf Accessed May 28, 2007.
5. Carver BS, Motzer RJ, Kondagunta GV, Sogani PG, Sheinfeld J. Late relapse of testicular germ cell tumors. Urol Oncol. 2005;23:441-145.
6. Aass N, Hepp O, Cavallin-Stahl E, et al. Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: a multicenter experience. J Clin Oncol. 1991;9:818-826.
7. Fossa SD, Qvist H, Stenwig AE, Lien HH, Ous S, Giercksky KE. Is postchemotherapy retroperitoneal surgery necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses? J Clin Oncol. 1992;10:569-573.
8. Steyerberg EW, Keizer HJ, Fossa SD, et al. Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from 6 study groups. J Clin Oncol. 1995;13:1177-1187.
9. Toner GC, Panicek DM, Heelan RT, et al. Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. J Clin Oncol. 1990;8:1683-1694.
10. Fossa SD, Ous S, Lien HH, Stenwig AE. Post-chemotherapy lymph node histology in radiologically normal patients with metastatic nonseminomatous testicular cancer. J Urol. 1989;141:557-559.
11. Oldenburg J, Alfsen GC, Lien HH, Aass N, Waehre H, Fossa SD. Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses. J Clin Oncol. 2003;21:3310-3317.
12. Beck SD, Foster RS, Bihrle R, et al. Teratoma in the orchiectomy specimen and volume of metastasis are predictors of retroperitoneal teratoma in post-chemotherapy nonseminomatous testis cancer. J Urol. 2002;168:1402-1404.
13. Donohue JP, Rowland RG, Kopecky K, et al. Correlation of computerized tomographic changes and histological findings in 80 patients having radical retroperitoneal lymph node dissection after chemotherapy for testis cancer. J Urol. 1987;137:1176-1179.
14. [No authors listed.] International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers.International Germ Cell Cancer Collaborative Group. J Clin Oncol. 1997;15:594-603.
15. Baniel J, Foster RS, Gonin R, Messemer JE, Donohue JP, Einhorn LH. Late relapse of testicular cancer. J Clin Oncol. 1995;13:1170-116.
16. Baniel J, Foster RS, Einhorn LH, Donohue JP. Late relapse of clinical stage I testicular cancer. J Urol. 1995;154:1370-1372.
17. Carver BS, Bianco FJ Jr, Shayegan B, et al. Predicting teratoma in the retroperitoneum in men undergoing post-chemotherapy retroperitoneal lymph node dissection. J Urol. 2006;176:100-103.
18. Motzer RJ, Amsterdam A, Prieto V, et al. Teratoma with malignant transformation: diverse malignant histologies arising in men with germ cell tumors. J Urol. 1998;159:133-138.
19. Eggener SE, Carver BS, Sharp DS, Motzer RJ, Bosl GJ, Sheinfeld J. Incidence of disease outside modified retroperitoneal lymph node dissection templates in clinical stage I or IIA nonseminomatous germ cell testicular cancer. J Urol. 2007;177:937-942.